Release

ADVENTRX Pharmaceuticals to Present at the OneMedForum Business Development and Investment Conference on June 23

SAN DIEGO, June 16, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the OneMedForum Business Development and Investment Conference on Thursday June 23rd, 2011, at 10:30am Eastern time, in the Plaza Room at the Roosevelt Hotel in New York.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates. Two of the Company's lead product candidates, Exelbine(TM), or ANX-530 (vinorelbine injectable emulsion) and ANX-514 (docetaxel emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs. The Company's other lead product candidate, ANX-188, is a novel, purified, rheologic and antithrombotic compound, which initially is being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis. More information can be found on the Company's web site at www.adventrx.com.

SOURCE ADVENTRX Pharmaceuticals, Inc.